Search

Displaying results 3101 - 3110 of 9670 in total
  1. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

  2. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized … [L50642] As CXCR4 mutations have also been implicated in human immunodeficiency virus (HIV), Waldenstrom’s macroglobulinemia (WM), B-cell non-Hodgkin lymphoma, and solid tumours, including melanoma,

  3. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI.

  4. Drug

    Chlormerodrin Hg-197

    go.drugbank.com/drugs/DB09406
    Approved

    Chlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.

  5. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  6. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  7. Drug

    Natamycin

    go.drugbank.com/drugs/DB00826
    ApprovedInvestigational

    It is used for a variety of fungal infections, mainly topically. [PubChem]

  8. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  9. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label]. … Crotalus atrox antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus atrox (Western Diamondback rattlesnake).

  10. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]